See more : Imdex Limited (IMD.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Kidswell Bio Corporation (4584.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kidswell Bio Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Pickles Corporation (2925.T) Income Statement Analysis – Financial Results
- NorthPoint Communications Group Inc. (NPNTQ) Income Statement Analysis – Financial Results
- Larimar Therapeutics, Inc. (LRMR) Income Statement Analysis – Financial Results
- Mopoli Fond (MOPF.BR) Income Statement Analysis – Financial Results
- China Green Agriculture, Inc. (CGA) Income Statement Analysis – Financial Results
Kidswell Bio Corporation (4584.T)
About Kidswell Bio Corporation
Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease. In addition, its products also include GCT-101 for alveolar cleft; GCT-102 for congenital isolated hypoganglionosis; and other pipeline products for ophthalmologic diseases, cerebral palsy, peripheral nerve palsy, fracture, and spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.43B | 2.78B | 1.57B | 996.54M | 1.08B |
| Cost of Revenue | 1.39B | 1.25B | 550.36M | 119.57M | 654.00M |
| Gross Profit | 1.04B | 1.53B | 1.02B | 876.97M | 423.00M |
| Gross Profit Ratio | 42.75% | 54.96% | 64.93% | 88.00% | 39.28% |
| Research & Development | 1.45B | 1.22B | 903.06M | 963.87M | 898.00M |
| General & Administrative | 163.96M | 182.93M | 101.90M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 163.96M | 182.93M | 101.90M | 883.00M | 687.00M |
| Other Expenses | 757.67M | -27.78M | 30.87M | 1.72M | 0.00 |
| Operating Expenses | 2.37B | 2.08B | 1.67B | 1.85B | 7.73B |
| Cost & Expenses | 3.77B | 3.33B | 2.22B | 1.97B | 8.39B |
| Interest Income | 8.00K | 12.00K | 936.00K | 52.00K | 117.00K |
| Interest Expense | 38.78M | 34.84M | 15.46M | 15.69M | 5.21M |
| Depreciation & Amortization | 921.00K | 932.00K | 2.30M | 992.00K | 321.00K |
| EBITDA | -1.38B | -620.45M | -531.89M | -983.00M | -7.31B |
| EBITDA Ratio | -56.80% | -21.22% | -39.92% | -97.79% | -107.86% |
| Operating Income | -1.34B | -550.93M | -651.14M | -969.69M | -1.16B |
| Operating Income Ratio | -54.93% | -19.84% | -41.49% | -97.31% | -107.89% |
| Total Other Income/Expenses | -84.93M | -105.30M | 101.49M | -29.99M | -6.15B |
| Income Before Tax | -1.42B | -656.22M | -549.65M | -999.68M | -7.31B |
| Income Before Tax Ratio | -58.43% | -23.64% | -35.03% | -100.31% | -679.11% |
| Income Tax Expense | 1.55M | 1.21M | 1.21M | 1.78M | 2.00M |
| Net Income | -1.42B | -657.43M | -550.86M | -1.00B | -7.32B |
| Net Income Ratio | -58.49% | -23.68% | -35.10% | -100.49% | -679.29% |
| EPS | -40.23 | -20.77 | -17.86 | -34.79 | -264.64 |
| EPS Diluted | -40.23 | -20.77 | -17.86 | -34.79 | -264.64 |
| Weighted Avg Shares Out | 35.34M | 31.65M | 30.85M | 28.79M | 27.65M |
| Weighted Avg Shares Out (Dil) | 35.34M | 31.65M | 30.85M | 28.79M | 27.65M |
Source: https://incomestatements.info
Category: Stock Reports